Last reviewed · How we verify
Ibandronate IV
Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Osteoporosis in postmenopausal women, Bone metastases and hypercalcemia of malignancy, Paget's disease of bone.
At a glance
| Generic name | Ibandronate IV |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Bisphosphonate |
| Target | Farnesyl pyrophosphate synthase; hydroxyapatite in bone |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Osteoporosis |
| Phase | FDA-approved |
Mechanism of action
As a nitrogen-containing bisphosphonate, ibandronate accumulates in bone and is taken up by osteoclasts during bone resorption. It inhibits farnesyl pyrophosphate synthase, disrupting the prenylation of small GTPases essential for osteoclast function, leading to osteoclast apoptosis and reduced bone turnover. This mechanism makes it effective for conditions characterized by excessive bone loss.
Approved indications
- Osteoporosis in postmenopausal women
- Bone metastases and hypercalcemia of malignancy
- Paget's disease of bone
Common side effects
- Osteonecrosis of the jaw
- Atypical femoral fractures
- Musculoskeletal pain
- Nausea
- Renal impairment
Key clinical trials
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation (PHASE4)
- Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases (PHASE2)
- Denosumab Safety Assessment in Multiple Observational Databases
- S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. (PHASE3)
- A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease (PHASE3)
- A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease. (PHASE2)
- A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain (PHASE3)
- Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ibandronate IV CI brief — competitive landscape report
- Ibandronate IV updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI